SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Tiangang Li, John Y.L. Chiang, Bile acids as metabolic regulators, Current Opinion in Gastroenterology, 2015, 31, 2, 159

    CrossRef

  2. 2
    Achint Kaur, Jay V. Patankar, Willeke de Haan, Piers Ruddle, Nadeeja Wijesekara, Albert K. Groen, C. Bruce Verchere, Roshni R. Singaraja, Michael R. Hayden, Loss ofCyp8b1Improves Glucose Homeostasis by Increasing GLP-1, Diabetes, 2015, 64, 4, 1168

    CrossRef

  3. 3
    A. Brønden, M. Hansen, D. P. Sonne, U. Rohde, T. Vilsbøll, F. K. Knop, Sevelamer in a diabetologist's perspective: a phosphate-binding resin with glucose-lowering potential, Diabetes, Obesity and Metabolism, 2015, 17, 2
  4. 4
    Elin Org, Margarete Mehrabian, Aldons J. Lusis, Unraveling the environmental and genetic interactions in atherosclerosis: Central role of the gut microbiota, Atherosclerosis, 2015, 241, 2, 387

    CrossRef

  5. 5
    Folkert Kuipers, Vincent W. Bloks, Albert K. Groen, Beyond intestinal soap—bile acids in metabolic control, Nature Reviews Endocrinology, 2014, 10, 8, 488

    CrossRef

  6. 6
    Morten Hansen, David P. Sonne, Filip K. Knop, Bile Acid Sequestrants: Glucose-Lowering Mechanisms and Efficacy in Type 2 Diabetes, Current Diabetes Reports, 2014, 14, 5

    CrossRef

  7. 7
    D. P. Sonne, M. Hansen, F. K. Knop, MECHANISMS IN ENDOCRINOLOGY: Bile acid sequestrants in type 2 diabetes: potential effects on GLP1 secretion, European Journal of Endocrinology, 2014, 171, 2, R47

    CrossRef

  8. 8
    Michelle Pearlman, Rohit Loomba, State of the art, Current Opinion in Gastroenterology, 2014, 30, 3, 223

    CrossRef

  9. 9
    Akiko Eguchi, Davide Povero, Naim Alkhouri, Ariel E Feldstein, Novel therapeutic targets for nonalcoholic fatty liver disease, Expert Opinion on Therapeutic Targets, 2013, 17, 7, 773

    CrossRef

  10. 10
    G. Smushkin, M. Sathananthan, F. Piccinini, C. Dalla Man, J. H. Law, C. Cobelli, A. R. Zinsmeister, R. A. Rizza, A. Vella, The Effect of a Bile Acid Sequestrant on Glucose Metabolism in Subjects With Type 2 Diabetes, Diabetes, 2013, 62, 4, 1094

    CrossRef

  11. 11
    Thuy-Anh Le, Joshua Chen, Christopher Changchien, Michael R. Peterson, Yuko Kono, Heather Patton, Benjamin L. Cohen, David Brenner, Claude Sirlin, Rohit Loomba, Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: A randomized controlled trial , Hepatology, 2012, 56, 3
  12. 12
    Lisa M Younk, Stephen N Davis, Evaluation of colesevelam hydrochloride for the treatment of type 2 diabetes, Expert Opinion on Drug Metabolism & Toxicology, 2012, 8, 4, 515

    CrossRef

  13. You have free access to this content13
    A. Zarrinpar, R. Loomba, Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease, Alimentary Pharmacology & Therapeutics, 2012, 36, 10
  14. 14
    Taoufiq Harach, Thijs W. H. Pols, Mitsunori Nomura, Adriano Maida, Mitsuhiro Watanabe, Johan Auwerx, Kristina Schoonjans, TGR5 potentiates GLP-1 secretion in response to anionic exchange resins, Scientific Reports, 2012, 2,

    CrossRef